| Autor: |
Alessandro Vinciguerra, Andrea Rampi, Mona-Rita Yacoub, Moreno Tresoldi, Umberto Tanzini, Mario Bussi, Matteo Trimarchi |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 279(11) |
| ISSN: |
1434-4726 |
| Popis: |
Biological therapies are gaining relevance in the management of CRSwNP with few adverse events reported. Among these, dupilumab, an anti-IL4-Ra monoclonal antibody, is frequently associated with hypereosinophilia (HE) which usually remains silent and progressively resolves, although some cases of systemic involvement occurs. The aim of this paper is to describe our experience and propose a management flowchart for HE during therapy with dupilumab.Patients with CRSwNP who satisfied EPOS2020 criteria for biological therapies were included in this prospective study. Each case was discussed in a multidisciplinary meeting with subsequent prescription of dupilumab; all patients were candidates to follow-up bi-monthly for 6 months, while additional blood tests were scheduled in the event of HE.A total of 21 patients with a mean age of 48.4 years were enrolled. Of these, 15 of 21 presented an asthma comorbidity and 9 of 21 ASA sensitivity. Four patients (19%) developed HE with AEC 1.5 × 10During dupilumab therapy, HE may occur and should be considered benign when 3 × 10 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink